DNAPrint Genomics

DNAPrint Genomics Current Liabilities

The Current Liabilities of DNAPrint Genomics (DNAG) as of Sep 25, 2026 is 17.38 M USD. In the previous year, Current Liabilities was 11.07 M USD — a change of 57.00% (higher).

Current Liabilities

17.38 MUSD

YoY

57.00%

Last updated:

Current Liabilities of DNAPrint Genomics is 2026 17.38 M USD. Current Liabilities of DNAPrint Genomics was 2025 11.07 M USD. It decreases by 57.00% higher compared to the previous year.

The DNAPrint Genomics Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2000
252,000.00 USD
Jan 1, 2001
352,148.00 USD
Jan 1, 2002
1.65 M USD
Jan 1, 2003
4.08 M USD
Jan 1, 2004
2.49 M USD
Jan 1, 2005
11.07 M USD
Jan 1, 2006
17.38 M USD
The DNAPrint Genomics Current Liabilities history
YEARCurrent LiabilitiesYoY
17.38 MUSD+57.00%
11.07 MUSD+344.40%
2.49 MUSD-38.96%
4.08 MUSD+147.36%
1.65 MUSD+368.39%
352,148.00USD+39.74%
252,000.00USD—
Access this data via the Eulerpool API

DNAPrint Genomics Stock analysis

What does DNAPrint Genomics do? DNAPrint Genomics Inc. was an American company specializing in researching genetic differences and their impact on health, diagnostics, and forensic applications. Founded in Sarasota, Florida in 1997, originally named Genaissance Pharmaceuticals, the company focused on medical research. In 2005, it changed its name to DNAPrint Genomics and shifted its focus to genetic testing development. The company's business model included developing and marketing molecular tests that can reveal an individual's genetic background, providing access to new markets and customers. DNAPrint Genomics offered various product lines for disease diagnosis, including tests for identifying and diagnosing specific diseases like breast cancer, colon cancer, and Alzheimer's. They also provided diagnostics for personalized medicine, matching medication to individuals' genetic predispositions. However, the company gained attention primarily for its forensic applications. They developed a system called DNAWitness, allowing comparison of unknown DNA samples with DNA databases to create offender profiles. The system was used by law enforcement agencies in the U.S. to aid crime investigation and was also involved in international police collaborations. DNAPrint Genomics pursued patents and partnerships with other companies to expand access to new technologies and developments, aiming to position itself in the international market. In 2008, the company announced its discontinuation due to economic reasons, facing complications in selling its DNAWitness system and encountering difficulties in selling its diagnostic tests. Despite having promising products, the company was unable to stabilize its market position and become profitable. DNAPrint Genomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DNAPrint Genomics stock

Current Liabilities of DNAPrint Genomics is 17.38 M USD in 2026.

Current Liabilities of DNAPrint Genomics changed from 11.07 M USD to 17.38 M USD, representing a 57.00% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities DNAPrint Genomics since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's DNAPrint Genomics historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — DNAPrint Genomics

All Key Metrics — DNAPrint Genomics